Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose Sugammadex and Neostigmine for Neuromuscular Block Reversal in Obese Patients
NCT03328312Phase 1Unknown
- Sponsor
- Iuliu Hațieganu University of Medicine and Pharmacy
- Start
- Dec 2017
- Primary completion
- Mar 2018
- Modality
- Biodegradable Polymers, Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of Sugammadex in neuromuscular blockade (NMB), sponsored by Iuliu Hațieganu University of Medicine and Pharmacy. Status: unknown.
02
Drugs
Sugammadex
03
Conditions
neuromuscular blockade (NMB)
Beyond the preview
Go deeper on NCT03328312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03328312.